Home › Sclerosing Cholangitis
Pag-aaral pangklinika para sa Sclerosing Cholangitis na nagre-recruit sa U.S.
17 pag-aaral para sa Sclerosing Cholangitis ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
Ayos sa estado
- California7 pag-aaral
- Colorado3 pag-aaral
- Maryland3 pag-aaral
- Minnesota4 pag-aaral
- Ohio4 pag-aaral
- Texas3 pag-aaral
- Washington4 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 90 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT04685200A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
Nagre-recruitPhase 3
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Ago 31, 2026 · NCT07387549A-LiNK: Improving Outcomes in Autoimmune Liver Disease
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT05750498MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
Nagre-recruitObservasyonal na pag-aaral
Edad 6 hanggang 23 · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT03178630MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
Nagre-recruitObservasyonal na pag-aaral
Edad 6 hanggang 23 · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT03175471Detoxification of the Liver In PSC (Dolphin)
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Hul 21, 2026 · NCT05835505Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Hul 17, 2026 · NCT06905054Primary Sclerosing Cholangitis in Children
Nagre-recruitObservasyonal na pag-aaral
Edad 2 hanggang 25 · Lahat ng kasarian · Na-update Hul 14, 2026 · NCT04181138Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC
Nagre-recruitMaagang Phase 1
Edad 18 hanggang 76 · Lahat ng kasarian · Na-update May 20, 2026 · NCT06197308A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)
Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 68 · Lahat ng kasarian · Na-update Mar 5, 2026 · NCT07229911Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
Nagre-recruitMaagang Phase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Peb 27, 2026 · NCT05912387Biobank for Cholestatic Liver Diseases.
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 85 · Lahat ng kasarian · Na-update Peb 17, 2026 · NCT03445585Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 85 · Lahat ng kasarian · Na-update Peb 17, 2026 · NCT04753996A Study of SIPLIZUMAB in AILD and LT Patients
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 24, 2025 · NCT06455280A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 24, 2025 · NCT06699121Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
Nagre-recruitPhase 2
Edad 14 hanggang 75 · Lahat ng kasarian · Na-update Hun 13, 2025 · NCT05295680Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
2 Weeks – 40 Years · Lahat ng kasarian · Na-update Nob 15, 2016 · NCT02137668Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.